Lilly_art

Eli Lilly’s earnings: Earn $1,300, and buy shares cheaper

Want to own Eli Lilly shares, but not at today's price? What if you could collect a premium while waiting for a better entry point?

With Eli Lilly's earnings approaching on 29 October, investors may have an opportunity to explore exactly that through a strategy called a cash-secured put.

The idea is simple: collect an option premium upfront and agree to buy shares at a lower price if they fall below a level you choose. If the shares stay above that level through expiry, you can keep the premium without buying the stock.

With Eli Lilly's earnings approaching on 29 October, investors may have an opportunity to explore exactly that through a strategy called a cash-secured put.

The idea is simple: collect an option premium upfront and agree to buy shares at a lower price if they fall below a level you choose. If the shares stay above that level through expiry, you can keep the premium without buying the stock.

Of course, there is a catch: if the stock falls sharply, you may have to buy it at a price above its market value.

Why Eli Lilly, and why now?

While much of the market's attention has been on AI stocks and concerns about their valuations and rising investment costs, Eli Lilly (NYSE: LLY) has been riding a different growth story.

Shares are up around 16% year-to-date, supported by booming demand for its diabetes and weight-loss treatments, Mounjaro and Zepbound.

In the second quarter of 2026, Lilly reported:

  • 48% revenue growth to US$23 billion.
  • Strong demand for its obesity and diabetes medicines.
  • Higher full-year revenue guidance, reflecting continued business momentum.

For investors with significant exposure to technology and AI, healthcare also offers diversification. Lilly's growth depends more on demand for medicines than on AI infrastructure spending.

But after a strong rally, some investors may hesitate to buy the stock at today's price.

This is where a cash-secured put could become interesting: instead of chasing the stock higher, investors can potentially get paid while waiting for a lower entry price.

What is a cash-secured put?

A cash-secured put is an options strategy where you sell a put option and receive a premium upfront in exchange for accepting the obligation to buy shares at a predetermined price if assigned.

Because the strategy is "cash-secured", you set aside enough cash to purchase the shares if assignment occurs. Since one options contract typically represents 100 shares, you must reserve sufficient funds to buy 100 shares at the strike price.

Many investors use this strategy when they would be comfortable owning a stock, but only at a lower price than where it currently trades.


A case study with Eli Lilly

Suppose you'd be happy to buy Eli Lilly shares, but only if they fell to a lower level than the current market price.

You could sell the 30 October 2026 (one day after its scheduled earnings announcement) US$1,155 put option.

Key contract details:

  • Current share price: US$1,251.25
  • Strike price: US$1,155
  • Option premium received (last traded): US$13.00 per share
  • Contract size: 100 shares
  • Expiry: 30 October 2026
  • Delta:-0.18

By selling one contract, you would receive approximately:

US$13.00 × 100 = US$1,300

This premium is yours to keep regardless of what happens later, provided you maintain the position.

Because the strategy is cash-secured, you would set aside:

US$1,155 × 100 = US$115,500

If assignment occurs, your effective purchase price becomes:

US$1,155 − US$13 = US$1,142 per share (~9% discount to current price)

Your break-even price is therefore US$1,142.


How Could This Play Out?

At option expiry

Share price

What happens

Result

Shares remain above the strike

Above US$1,155

Put expires worthless

You keep the full US$1,300 premium. No shares are purchased.

Shares fall below the strike

Below US$1,155

Assignment occurs and you buy 100 shares at US$1,155

Losses may occur if the share price is below the US$1,142 break-even level.


What are the risks?

There are both company-specific and strategy-specific risks to consider.

For Eli Lilly, investor attention remains focused on demand trends for its diabetes and obesity treatments, execution of its product pipeline, clinical trial outcomes, and regulatory developments. Recent company updates have also highlighted continued expansion of its obesity and immunology franchises, including positive clinical data announcements.

Some key risks include:

  • Slower-than-expected growth in obesity or diabetes products.
  • Unexpected clinical trial setbacks.
  • Regulatory or reimbursement changes.
  • Increased competition from other pharmaceutical companies.
  • Earnings results that fail to meet elevated market expectations.

From a strategy perspective:

  • The stock can decline significantly after earnings.
  • The premium received provides only limited downside protection.
  • Assignment can occur, requiring substantial capital.
  • Capital remains tied up while the position is open.

A cash-secured put should therefore only be considered if you are genuinely comfortable owning the shares at the effective purchase price.


Why might this appeal to a long-term investor?

Some long-term investors view cash-secured puts as a way to get paid while waiting for a potentially lower entry price.

Rather than placing a limit order at US$1,155, you could sell a put and collect premium income while waiting. If the shares remain above the strike, you keep the premium. If the shares decline and assignment occurs, you acquire the shares at an effective cost basis of approximately US$1,142, which is lower than the strike price because of the premium received.

The strategy does not eliminate risk, but it may be attractive to investors who already have a long-term interest in owning the company and have the cash available to purchase shares if required.


Key Definitions

Strike Price
The price at which you may be required to buy shares if assigned.

Premium
The amount received upfront for selling the option.

Assignment
The process through which the option seller becomes obligated to buy shares at the strike price.

Expiry
The date on which the option contract ceases to exist.

Break-Even Price
The strike price minus the premium received. In this example: US$1,142.

Cash-Secured
A position where enough cash is reserved to purchase the shares if assignment occurs.

Delta
An options metric indicating how sensitive the option price is to movements in the underlying share price. The selected contract has a delta of approximately-0.18, suggesting a relatively low probability of finishing in-the-money.

Disclaimer

Confidentiality and Usage:
You may not reproduce, distribute, or transmit this material or any portion thereof without prior written permission from Saxo.

Nature of Information:
The information provided herein is based on current market conditions and analysts' opinions, which may reflect personal views of the author, and are subject to change without notice. This material does not include a record of any trading prices, or an offer of, or solicitation for, or endorsement to enter into any transaction in any investment product. Any forecast on the economy, markets and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the investment product subject of this material.

Responsibility and Liability:
Saxo accepts no liability for any use that may be made of these comments or for any consequences that arise from such use. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

The information provided in this material is solely for information only. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning specific situations of any person. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase an investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether any investment product mentioned in this publication is suitable for you.

Notwithstanding the above, insofar as any information provided herein contains research analyses or reports concerning any investment product authored by any foreign research house and is issued or promulgated to a person in Singapore who is not an accredited investor, expert investor, and/or institutional investor, Saxo Capital Market Pte. Ltd. accepts legal responsibility for the contents of this material to the extent required by law. Recipients of such material are to contact Saxo Capital Markets Pte. Ltd. in respect of any matters arising from, or in connection with, this material.

Risk Disclosure:
Trading in investment products involve significant risk, including the risk of losing your entire investment. Historical returns are not a guarantee of future returns. Prices can both rise and fall, and there is a risk that you will not get back the money you invested.

Conflicts of interest:
The author may hold positions in the investment products mentioned. The author does not own positions in the underlying investment product exceeding 0.5% of its market capitalisation, save as otherwise declared. The author is not permitted to trade the mentioned investment products within the first 24 hours after the publication of this article.

Saxo maintains partnerships with companies that compensate Saxo for promotional activities conducted on its platform. Additionally, Saxo has agreements with certain partners who provide retrocession contingent upon clients purchasing specific investment products offered by these partners. While Saxo receives compensation from these partnerships, all content is conducted with the intention of providing clients with valuable options and information.

Publication details:
If any listed companies are the subject of the material, the content has not been submitted to the companies in question prior to publication.

Please refer to our full disclaimer and notification on non-independent investment research for more details.

Saxo Markets
88 Market Street
CapitaSpring #31-01
Singapore 048948

Contact Saxo

Singapore
Singapore

Saxo Capital Markets Pte Ltd ('Saxo Markets') is a company authorised and regulated by the Monetary Authority of Singapore (MAS) [Co. Reg. No.: 200601141M ] and is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms & Risk Warning to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Saxo is part of the J. Safra Sarasin Group.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Trading in leveraged products such as Margin FX products may result in your losses exceeding your initial deposits. Saxo Markets does not provide financial advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Markets does not take into account an individual’s needs, objectives or financial situation.

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-sg/about-us/awards.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website are not intended for residents of the United States, Malaysia and Japan. Please click here to view our full disclaimer.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.